within Pharmacolibrary.Drugs.ATC.C;

model C07AB12
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.125,
    Cl             = 4.9999999999999996e-06,
    adminDuration  = 600,
    adminMass      = 5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.01,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.005,
    Tlag           = 9.0,            
    Vdp             = 0.008,
    k12             = 0.25,
    k21             = 0.25
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C07AB12</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Nebivolol is a cardioselective beta-1 adrenergic receptor blocker with vasodilating properties due to nitric oxide modulation. It is used for the management of hypertension and heart failure. Nebivolol is approved and commonly used in clinical practice primarily for the treatment of high blood pressure.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after single oral administration of 5 mg nebivolol.</p><h4>References</h4><ol><li><p>Hanif, N, et al., &amp; Rasool, MF (2023). Clinical pharmacokinetics of nebivolol: a systematic review. <i>Drug metabolism reviews</i> 55(4) 428–440. DOI:<a href=&quot;https://doi.org/10.1080/03602532.2023.2271195&quot;>10.1080/03602532.2023.2271195</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37849071/&quot;>https://pubmed.ncbi.nlm.nih.gov/37849071</a></p></li><li><p>Sanaee, F, et al., &amp; Jamali, F (2013). Pharmacokinetics of nebivolol in the rat: low oral absorption, loss in the gut and systemic stereoselectivity. <i>Biopharmaceutics &amp; drug disposition</i> 34(6) 312–320. DOI:<a href=&quot;https://doi.org/10.1002/bdd.1847&quot;>10.1002/bdd.1847</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23625744/&quot;>https://pubmed.ncbi.nlm.nih.gov/23625744</a></p></li><li><p>Himmelmann, A, et al., &amp; Hedner, J (1996). Haemodynamic effects and pharmacokinetics of oral d- and l-nebivolol in hypertensive patients. <i>European journal of clinical pharmacology</i> 51(3-4) 259–264. DOI:<a href=&quot;https://doi.org/10.1007/s002280050194&quot;>10.1007/s002280050194</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9010695/&quot;>https://pubmed.ncbi.nlm.nih.gov/9010695</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C07AB12;
